1. Gross KM, Ponte CD. New strategies in the medical management of asthma. Am Fam Phys. 1998;58:89-100.
2.
2. Guidelines for the diagnosis and management of asthma. National Asthma Education Program. National Heart, Lung and Blood Institute, National Institute of Health, Bethesda, Maryland. Publication #91-3042 A. June 1991.
3.
3. Keller KA, Bhisitkul DM. Supraventricular tachycardia:a complication of nebulized albuterol. Pediatr Emerg Care. 1995;11:98-99.
5. Cook P, Scarfone RJ, Cook RT. Adenosine in the termination of albuterolinduced supraventricular tachycardia. Ann Emerg Med. 1994;24:316-319.
6.
6. Ludomirsky A, Garson A.Supraventricular tachycardia. In:Garson A, Bricker T, Fisher D, Neish S, eds. The Science and Practice of Pediatric Cardiology, 1st ed.Baltimore:Williams & Wilkins;1990:1809-1843.
7.
7. Till J, Shinebourne EA, Rigby ML, et al. Efficacy and safety of adenosine in the treatment of supraventricular tachycardia in infants and children. Br HeartJ. 1989;62:204-211.
8.
8. Rossi AF, Burton DA. Adenosine in altering short and long term treatment of supraventricular tachycardia in infants. Ann Emerg Med. 1992;21:1499-1501.
9.
9. Hall IP, Woodhead MA, Johnston ID. Effect of high dose salbutamol on cardiac rhythm in severe chronic airflow obstruction:a controlled study. Respiration. 1994;61:214-218.
10.
10. Lin RY, Smith AJ, Hergenroeder P.High serum albuterol levels and tachycardia in adult asthmatics treated with high dose continuously aerosolized albuterol. Chest. 1993;103:221-225.
